Adagio Medical, Inc., founded in 2011, is located in California, USA. Focus on research and development of new therapies for patients with cardiovascular diseases. The company's near critical nitrogen fluid catheter ablation products can produce ultra-low temperature and continuous transmural lesions. Compared with existing N2O based products, they have many advantages such as lower temperature, smaller catheter diameter, etc. This technology can produce safe and continuous transmural lesions to treat atrial flutter, ventricular tachycardia and arrhythmia, including paroxysmal and persistent atrial fibrillation. At present, the product is in clinical trial stage.